Published in Curr Opin HIV AIDS on January 01, 2009
Colorectal cancer screening in human immunodeficiency virus population: Are they at average risk? World J Gastrointest Oncol (2012) 0.82
Impact of HIV Infection on Medicare Beneficiaries with Lung Cancer. J Cancer Epidemiol (2012) 0.79
Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy. J Cancer Epidemiol (2016) 0.75
A case report of human immunodeficiency virus-associated anaplastic lymphoma kinase protein-negative anaplastic large cell lymphoma. Springerplus (2013) 0.75
Association between chronic hepatitis C and hepatitis C/HIV co-infection and the development of colorectal adenomas. J Gastrointest Oncol (2016) 0.75
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med (2008) 7.71
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Association of cancer with AIDS-related immunosuppression in adults. JAMA (2001) 6.80
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 6.69
Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis (2007) 3.75
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst (2000) 3.47
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst (2007) 3.28
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood (2006) 2.90
Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS (2008) 2.74
Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol (2006) 2.46
Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2008) 2.44
Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis (2004) 2.42
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Elevated risk of lung cancer among people with AIDS. AIDS (2007) 2.20
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS (2003) 2.15
Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS (2008) 2.14
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer (2005) 2.09
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS (2002) 1.98
Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr (2003) 1.96
Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr (2004) 1.90
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer (2008) 1.70
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS (2008) 1.60
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med (2002) 1.59
Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis (2005) 1.58
The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction (2008) 1.58
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol (2008) 1.52
Risk of cancer in people with AIDS. AIDS (1999) 1.47
Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40
The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (2007) 1.40
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer (2004) 1.39
Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma (2005) 1.36
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS (1998) 1.32
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res (2002) 1.31
HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res (2007) 1.30
AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol (2007) 1.25
Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr (2004) 1.24
Cancer incidence in women with or at risk for HIV. Int J Cancer (2001) 1.23
Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood (2002) 1.21
Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr (2002) 1.13
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res (2004) 1.13
Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS (1999) 1.12
Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr (2001) 1.09
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol (2003) 1.09
Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr (2008) 1.04
Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS (1997) 1.03
Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer (1999) 0.91
Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS (1997) 0.87
Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses (2008) 0.80
Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS (1997) 0.78
Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control (2008) 0.76
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med (2003) 4.27
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol (2009) 2.35
It's time for clinicians to reconsider their proscription against the use of soyfoods by breast cancer patients. Oncology (Williston Park) (2013) 2.07
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.02
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med (2009) 1.63
Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr (2008) 1.49
Contrasts, conflicts, and change: A case in cultural oncology. J Support Oncol (2006) 1.40
AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol (2007) 1.25
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS (2012) 1.07
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis (2013) 0.98
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS (2011) 0.98
Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res (2012) 0.96
Medicinal cannabis: rational guidelines for dosing. IDrugs (2004) 0.94
Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr (2014) 0.94
Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J Acquir Immune Defic Syndr (2006) 0.91
Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2. Clin Infect Dis (2003) 0.90
Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol (2002) 0.89
Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial. Evid Based Complement Alternat Med (2012) 0.86
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS (2002) 0.85
The efficacy of distant healing for human immunodeficiency virus--results of a randomized trial. Altern Ther Health Med (2006) 0.83
Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther (2011) 0.83
The BraveNet prospective observational study on integrative medicine treatment approaches for pain. BMC Complement Altern Med (2013) 0.82
Integrating dietary supplements into cancer care. Integr Cancer Ther (2013) 0.81
Massage for children undergoing hematopoietic cell transplantation: a qualitative report. Evid Based Complement Alternat Med (2012) 0.80
Patients seek integrative medicine for preventive approach to optimize health. Explore (NY) (2012) 0.80
Non-AIDS-Defining Malignancies in the HIV-Infected Population. Curr Infect Dis Rep (2014) 0.78
Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Care (2011) 0.77
Assessing the Association between Leptin and Bone Mineral Density in HIV-Infected Men. AIDS Res Treat (2012) 0.77
Can clinicians now assure their breast cancer patients that soyfoods are safe? Womens Health (Lond Engl) (2010) 0.76
New insights into the role of HIV infection on cancer risk. Lancet Oncol (2009) 0.75
Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival. AIDS (2015) 0.75
What's the alternative? N Engl J Med (2012) 0.75
Nausea at the end of adjuvant cancer treatment in relation to exercise during treatment in patients with breast cancer. Oncol Nurs Forum (2008) 0.75
Using Medical Cannabis in an Oncology Practice. Oncology (Williston Park) (2016) 0.75
Not soy simple. J Soc Integr Oncol (2010) 0.75